MedTrace Logo

An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough

NCT01703923 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2014-11-05

No results posted yet for this study

Summary

The purpose of this study is to determine the antitussive effect size and dose response of FP01 lozenges in subjects with chronic cough and to demonstrate the safety and tolerability of FP01 lozenges in subjects with chronic cough.

Conditions

  • Chronic Refractory Cough

Interventions

DRUG

FP01

DRUG

placebo

Sponsors & Collaborators

  • Avalo Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Blake Paterson, MD · Avalo Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01703923 on ClinicalTrials.gov